Next Article in Journal
Medical Treatment of Obstructive Sleep Apnea in Children
Previous Article in Journal
Direct Anterior vs. Direct Lateral Approach Total Hip Arthroplasty for Displaced Femoral Neck Fracture
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 15
10.3390/jcm12155020
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Changes in Antibiotic Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Clinical Isolates in a Multi-Profile Hospital in Years 2017–2022 in Wroclaw, Poland

by
Beata Mączyńska
1,
Agnieszka Jama-Kmiecik
2,*,
Jolanta Sarowska
2,
Krystyna Woronowicz
3,
Irena Choroszy-Król
2,
Daniel Piątek
4 and
Magdalena Frej-Mądrzak
2
1
Department of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Medical University, 50-367 Wroclaw, Poland
2
Department of Basic Sciences, Faculty of Health Sciences, Medical University, 50-367 Wroclaw, Poland
3
Medical Laboratory Synevo, Fieldorfa 2, 50-049 Wroclaw, Poland
4
Lower Silesian T. Marciniak Specialist Hospital-Center for Emergency Medicine, 54-049 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(15), 5020; https://doi.org/10.3390/jcm12155020
Submission received: 22 June 2023 / Revised: 20 July 2023 / Accepted: 27 July 2023 / Published: 30 July 2023
(This article belongs to the Section Infectious Diseases)
Browse Figures
Versions Notes

Abstract

:
In recent years, we have witnessed increasing drug resistance among bacteria, which is associated with the use and availability of an increasing number of broad-spectrum antimicrobials, as well as with their irrational and excessive use. The present study aims to analyze changes in the drug resistance of Gram-negative Pseudomonas aeruginosa and Acinetobacter baumannii, isolated from infections in a multi-profile hospital over a five-year period (from 2017 to 2022). Among the practical results of the evaluation of these data will be the possibility to determine changes in susceptibility to the antibiotics used in the hospital. This, in turn, will help propose new therapeutic options, especially for empirical therapy, which is essential in severe infections. Analysis of the use of different antibiotic groups has made it possible to identify the causes of increasing resistance in the analyzed Gram-negative bacilli. The highest antibiotic use was observed in the hospital between 2020 and 2022, most probably due to the COVID-19 pandemic and the higher number of patients in severe condition requiring hospitalization. Unfortunately, during the period analyzed, the number of multi-resistant strains of A. baumannii was successively increasing; this seems to be related to the increased use, especially during the pandemic period, of broad-spectrum antibiotics, mainly penicillins with inhibitors, third-generation cephalosporins and carbapenems.

1. Introduction

In order to gather information on the prevention and control of infections and infectious diseases, the tasks and management of disease outbreaks or threats of disease outbreaks are defined, including the definition of an infectious disease as any disease caused by a pathogenic biological agent, and an alarming agent as a pathogenic agent with high virulence or resistance. Antimicrobial resistance could result in the global loss of 10 million lives per year by 2050 [1]. Strains showing acquired resistance to at least one antibiotic in a minimum of three significant groups (MDR) are of greatest concern. There are also XDR and PDR strains, which means resistance to at least one antibiotic of each group and insensitivity to all available therapeutics, respectively [2]. Apart from Staphylococcus aureus, Enterococcus spp., Escherichia coli, Klebsiella pneumoniae and Streptococcus pneumoniae, the most common bacterial carriers of resistance genes with high clinical relevance are Acinetobacter baumannii (A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa), and it is these bacteria and their resistance that were analyzed in this study [3].
P. aeruginosa are the etiologic agent of many hospital-acquired infections, especially in elderly or immunocompromised patients. It is estimated that P. aeruginosa is the etiologic agent of 10–20% of infections among hospitalized patients [4]. Increasing resistance of this pathogen to commonly used chemotherapeutics has become a major problem. A. baumannii and P. aeruginosa show natural resistance to penicillin G, aminopenicillins, first- and second-generation cephalosporins, macrolides, tetracyclines, chloramphenicol, quinolones, sulfonamides and trimethoprim. Such a wide lack of sensitivity of Pseudomonas is mainly due to poor outer membrane permeability, high activity of membrane pumps and the production of enzymes capable of hydrolyzing antibiotics. Decreased outer membrane permeability caused by loss of the porin protein OprD leads to increasing resistance to carbapenems. The active efflux mechanism, on the other hand, ensures the cell’s safety when drug molecules enter the cell. The ABC or MDR pumps transport drugs from cell, making it easier for bacteria to survive antimicrobial therapy. These resistance mechanisms make these bacilli a very difficult pathogen to eradicate [5]. An additional feature of P. aeruginosa is the presence in its chromosome of a gene encoding β-lactamase AmpC, whose production depends on the presence of a drug in the environment. The effect of the mutation can be constitutive production of this enzyme, without induction, eventually leading to widespread resistance to first-, second- and third-generation cephalosporins, penicillins (including those with inhibitors) and aztreonam. Of greatest clinical importance, however, are traits that P. aeruginosa acquires through horizontal gene transfer, most commonly through genes encoding β-lactamases. Many of these enzymes function as penicillinases that remain sensitive to carbapenems and oxyimino-cephalosporins, with PSE-1 being the most common among clinical strains. Mutations in these genes have led to the development of a new type of enzyme capable of degrading oxyimino-β-lactams as well. The first characterized and also the most common ESBL in these bacteria was the PER-1-type enzyme, which is characterized by intensive hydrolysis of ceftazidime [6].
Similar to P. aeruginosa, A. baumannii, due to their ability to survive in a wide range of environmental conditions (high resistance to desiccation and disinfectants), very often populate hospital wards, causing opportunistic infections, especially in critically ill and long-term hospitalized patients. Long-term hospital stays, ICU treatment, mechanical ventilation (ventilator-associated pneumonia, so-called VAP), broad-spectrum antibiotic therapy and recent surgical interventions are considered predisposing factors for infection. Like P. aeruginosa, A. baumannii is responsible for serious nosocomial infections, such as pneumonia, in patients on artificial ventilation and is also a cause of urinary tract infections, meningitis, wound infections and sepsis. The bacteria exhibit strong adhesion properties and multidrug resistance [7]. Infections caused by MDR bacteria in seriously ill patients in ICU wards cause a high risk of death (from 26% to 68%) [8]. The results of the study also confirmed the correlation between the resistance of these bacteria isolated from infections and mortality among patients, as well as between the type of infection and a significant increase in hospitalization time [9]. Strains of A. baumannii species show natural resistance to ampicillin, amoxicillin (also with an inhibitor), ceftazoline, cefotaxime, ceftriaxone, ertapenem, trimethoprim and fosfomycin. Sulbactam, on the other hand, is the only inhibitor that shows activity against these bacteria [10]. The production of AmpC-type (ADC) and OXA-51-like β-lactamases, as well as the presence of membrane pumps and the occurrence of insertion sequences, have been cited as reasons for such widespread natural resistance [11]. In addition to natural resistance, the bacteria also develop acquired resistance. The increased loss of sensitivity to carbapenems is a worrying phenomenon. The above is most often caused by the overlap of several resistance mechanisms: production of carbapenemases, reduction of outer membrane permeability and the efflux mechanism [12]. Regular analysis of changes in drug resistance is a very good tool for making changes in empirical therapy procedures and improving the effectiveness of antibiotic therapy. The main elements of antibiotic policy at the hospital level include properly administered empiric therapy, promotion of targeted therapy, perioperative antibiotic prophylaxis and a properly constructed hospital formulary [13]. Antibiotic consumption and the cost of antibiotic therapy are therefore subject to constant control through monitoring the drug resistance of isolated microorganisms and effective antibacterial therapy for patients, leading to a reduction in the number of nosocomial infections and an improvement in the epidemiological situation, thereby reducing the cost of antibiotic therapy [14].
Our study aimed to assess the drug resistance of P. aeruginosa and A. baumannii isolated from infections in a multi-profile hospital over a period of 6 years (from 2017 to 2022) and to determine trends among resistance mechanisms in these microorganisms in relation to the level of antibiotic consumption during the analyzed period.

2. Materials and Methods

2.1. Bacterial Strains

All the analyzed data came from the information and materials of the multi-profile hospital in Wroclaw and cover the period from 1 January 2017 to 31 December 2022. The materials were obtained from patients with nosocomial infections. In order to observe changes in the drug susceptibility of bacteria isolated from patients, 2 species of great importance from the point of view of drug resistance of pathogens were selected: P. aeruginosa and A. baumannii. These strains were isolated from nosocomial infections, mainly from pneumonia in patients undergoing artificial ventilation, urinary tract infections, surgical site infections and primary bloodstream infections. The number of strains between 2017 and 2022 is shown in Table 1. With the exception of 2021, the frequency of hospital infections caused by P. aeruginosa was significantly higher than that caused by A. baumannii.
Depending on the strain, resistance to specific selected antibiotics was analyzed.

2.2. Microbiological Assays

2.2.1. Automated Systems

The study was conducted according to the scheme: from the identification of strains through drug resistance analysis to the detection of carbapenemases by enzymatic and disk diffusion methods [15]. To identify microorganisms, strains were isolated from patient materials on appropriate microbiological media. Identification was made by evaluating colony morphology on plates and then using the VITEK®2 system (bioMerieux, Crappone, France). This system allows not only for confirmation of species affiliation, but also for the performance of antibiograms. This uses a bacterial suspension with a density of 0.5 on the McFarland scale and the corresponding identification and antibiogram cards. The corresponding VITEK®2 identification and antibiogram cards (AST-N331, GN ID), for the different microorganisms were placed in a VITEK®2 (bioMerieux, France), and a computer program identified and assessed the drug susceptibility of the strains. To assess drug susceptibility with the VITEK2 system, an antibiogram card for Gram-negative bacteria was used—VITEK2 AST-331 (amikacin, ampicillin/sulbactam, aztreonam, cefepime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin, piperacillin/tazobactam, ticarcillin/clavulanic acid, tobramycin, trimethoprim/sulfamethaxazole)—a set of 16 antibiotics (Table 2). The use of this system made it possible to determine MIC values. With some antibiotics absent from the VITEK panels, bacterial susceptibility was also tested using the antibiotic diffusion method (E-tests). The results obtained were interpreted in accordance with EUCAST recommendations [16,17].

2.2.2. The Disk Diffusion Method

A disk diffusion method was used to identify extended-spectrum β-lactamases (ESBLs). Disks with ceftazidime and cefotaxime were used, arranged at a distance of 2 cm (between the centers) from the disk with amoxicillin-clavulanic acid. A positive test result was recorded when there was a marked enlargement of the zone of inhibition around the disk with ceftazidime or cefotaxime (cefpodoxime, aztreonam) on the side of the disk containing clavulanic acid. This enlargement can take very different shapes [18,19].
In turn, disk methods were used to identify the type of carbapenemases. For the phenotypic test detecting KPC carbapenemases, a 10-μg meropenem disk and a 10-μg meropenem disk soaked in boronic acid were used, maintaining a minimum distance of 3 cm between them, and the plate was incubated at 35 °C for 18 h. In Pseudomonas spp. and Acinetobacter spp. a difference in zones of inhibition of ≥7 mm is considered a positive result. For the detection of MBL-class carbapenemases, sterile disks soaked in EDTA solution and disks with 30 μg ceftazidime and 10 μg imipenem were used, maintaining a 2 cm gap between them [20]. A positive result was considered to be an enlargement of the zone of inhibition around the disk with CAZ30 and/or IMP10 toward the disk with EDTA. Detection of OXA-48 carbapenemases was possible using a disk with 30 μg temocillin [18,19]. A reduction in the zone of inhibition around the TEM30 disk ≤10 mm was then observed.

2.2.3. Enzyme and Immunochromatographic Tests

The Carba NP enzyme assay (Argenta, Ferrara, Italy) allows detection of carbapenemases in P. aeruginosa and A. baumannii, but without determining their type. The test is based on the hydrolysis of imipenem by carbapenemases released from bacterial cell lysates suspended in buffer containing phenol red. As a result of the hydrolysis of imipenem, there is a change in the pH of the reaction environment (acidification), which is observed visually as a change in the color of phenol red to yellow or orange The difference in color in the test and control tubes indicates a positive test (carbapenemase production). The test was performed according to the recommendations of KORLD [21].
Resist O.O.K.N.V. immunochromatographic assays were also used to detect carbapenem hydrolyzing enzymes in the test strains. (Coris Bioconcept, Gembloux, Belgium). They allow the detection of carbapenemases KPC, OXA-163, OXA-48, NDM and VIM in Carbapenemase-producing organisms (CPOs), including Pseudomonas aeruginosa and Acinetobacter baumannii, which show resistance not only to beta-lactams and other groups of antibiotics, but also to carbapenems [21].

2.3. Statistical Analysis

The variables were expressed as a frequency: as an absolute value and as a percentage. Chi-square tests were used to compare categorical variables and Cochran–Armitage test for trends. Two-sided p-value < 0.05 indicated statistical significance. Statistical analyses were performed using Pipe-Friendly Framework for Basic Statistical Tests [R package ver. 0.7.0.]

3. Results

3.1. The Place of Isolate Pseudomonas aeruginosa and Acinetobacter baumanii Strains in Infections Detected at the Hospital during Period of 2017–2022

Non-fermenting bacilli are not frequently isolated microorganisms in the analyzed hospital. These strains rank fifth and sixth in frequency of isolation after E. coli, K. pneumoniae, S. aureus and E. faecium (Table 3). However, they are important pathogens causing severe infections, e.g., in the ICU.
The percentage of Pseudomonas aeruginosa strains in relation to other etiological agents of infection, shows a relatively constant level (7.4–6.2%) with a downward trend in recent years (Table 4). In the case of Acinetobacter baumanii, there was a clear increase in the percentage of strains in 2021, during the pandemic period (6.9%). However, in the following year, the percentage of these microorganisms decreased again (4.2%).

3.2. Antibiotic Resistance of P. aeruginosa Strains in 2017–2022

The analysis of changes in the resistance of non-fermenting P. aeruginosa included groups of antibiotics important from the point of view of therapy, such as cephalosporins, carbapenems, aminoglycosides and quinolones. Changes in the sensitivity of these bacteria to penicillins were not analyzed due to their natural resistance to these antibiotics.
Between 2017 and 2022, the number of P. aeruginosa strains was at a similar level, ranging from 146 in 2021 to 202 in 2018 (Figure 1). In the case of A. baumannii, a downward trend was noted between 2018 and 2020. In subsequent years, the number of Acinetobacter strains increased from 47 in 2019 to 160 in 2021. However, after the pandemic, another significant decrease in their number was noted in 2022. (Figure 1).
Resistance of P. aeruginosa to cephalosporins remained low, ranging from 11% (n = 16; 2022) to 27% (n = 55, 2018) for ceftazidime and from 7% (n = 10; 2022) to 30% (n = 61; 2018) for cefepime (Figure 2). In contrast, sensitivity to piperacillin with tazobactam was slightly lower, with the percentage of resistant strains ranging from 13% (n = 19; 2022) to 39% (n = 79; 2018) (Figure 2). Resistance to third- and fourth-generation cephalosporins and piperacillin with tazobactam was the highest in 2018, with the number of strains resistant to these three groups of antibiotics in the recent year (2022) by far the lowest compared to previous years. Resistance trends to cephalosporins and piperacillin with tazobactam are highly statistically significant p < 0.001.
The percentage of carbapenem-resistant strains has remained relatively stable and fairly low over the past 6 years, ranging from 14% (n = 21; 2021) to 30% (n = 61; 2018) for imipenem and from 14% (n = 21; 2022) to 32% (n = 65; 2018) for meropenem (Figure 3). The highest number of resistant strains was isolated from hospital-acquired infections in 2018, while the lowest was in 2022. Resistance trends for carbapenems are highly statistically significant p < 0.001.
Figure 4 shows that the highest percentage (86%) of P. aeruginosa strains susceptible to carbapenems was recorded in 2021. At the same time, among the strains resistant to carbapenems, only 4% produced carbapenemases (MBL type), the remaining majority (10%) had a transport mechanism of resistance (efflux or porin mutations in the cell wall). In 2022, the situation changed somewhat. P. aeruginosa strains sensitive to carbapenems prevailed, although the percentage decreased slightly (79%), at the expense of an increase in strains producing MBL carbapenemases (9%). The percentage of carbapenem-resistant strains that did not produce metallo-β-lactamases (MBL (−)) and whose resistance was due to a mechanism other than enzymatic was 12%, a figure similar to the previous year’s value (10%) (Figure 4).
Resistance in P. aeruginosa over the past 6 years has ranged between 7% (n = 10; 2021) and 30% (n = 61; 2018) for amikacin and between 8% (n = 12; 2021) and 29% (n = 59; 2018) for gentamicin (Figure 5). The most resistant strains were isolated in 2018, and a gradual increase in the susceptibility of these bacteria to aminoglycosides was observed starting in 2019. Aminoglycoside resistance trends are highly statistically significant p < 0.001.
The percentage of quinolone-resistant strains ranged from 15% (n = 22; 2022) to 55% (n = 111; 2018) for ciprofloxacin and from 17% (n = 25; 2022) to 61% (n = 123; 2018) for levofloxacin (Figure 6). The highest percentage of resistant strains was isolated in 2018, while the highest percentage of susceptible strains was observed in 2022. Quinolone resistance trends are highly statistically significant p < 0.001.

3.3. Antibiotic Resistance of A. baumannii Strains in 2017–2022

In purpose of observing the evolution of drug susceptibility of A. baumannii bacilli, the resistance of these strains to such antibiotic groups as carbapenems, aminoglycosides and quinolones was analyzed.
The percentage of carbapenem-resistant strains ranged from 28% (n = 13; 2019) to 79% (n = 126; 2021) for imipenem and from 25% (n = 12; 2019) to 76% (n = 122; 2021) for meropenem (Figure 7). The least resistant strains were isolated in 2019 and the most resistant in 2021. Resistance trends for carbapenems are highly statistically significant p < 0.001.
The percentage of aminoglycoside-resistant strains was quite high, ranging from 34% (n = 16; 2019) to 71% (n = 114; 2021) for amikacin and from 22% (n = 10; 2019) to 77% (n = 123; 2021) for gentamicin (Figure 8). The highest resistance was observed in 2021 and the lowest in 2019. A. baumannii showed higher resistance to aminoglycoside antibiotics than P. aeruginosa strains (Figure 5 and Figure 8). The trend of gentamicin resistance is highly statistically significant p < 0.001, while the trend for amikacin lacks statistical significance.
Among A. baumannii, quinolone resistance was observed, which was higher than that of P. aeruginosa (Figure 6 and Figure 9). The lowest percentage of resistant strains was observed in 2019–2020 and ranged from 48% (n = 23; 2019) to 50% (n = 10; 2019) for ciprofloxacin and from 45% (n = 21; 2019) to 53% (n = 35; 2020) for levofloxacin (Figure 9). In contrast, there was an increase in the percentage of strains resistant to ciprofloxacin in 2021, reaching 100% in 2022. The resistance trend for ciprofloxacin is highly statistically significant p < 0.001, while for levofloxacin it does not show such significance.
The analysis of antibiotic consumption in the hospital (in DDD/100 patient-days) over the studied 6-year period, showed a significant increase in consumption from 2020 to 2022 (Table 5). The lowest antibiotic consumption was recorded in 2019 (34.7), and the highest in 2022 (62.9). From 2017 to 2019, antibiotic consumption remained at a similar, relatively low level (between 44–34.7 DDD/100 persons) (Table 5).
Despite the highest hospital-wide consumption of antibiotics in the previous year, some drug groups saw a decrease in their consumption (Table 3). This applies, between 2020 and 2022, primarily to quinolones (from 12.7 to 7.3 DDD/100 person) and third-generation cephalosporins, mainly ceftriaxone (from 15.7 to 4.7 DDD/100 person). In contrast, the (already very high) use of penicillins with inhibitors (from 8.3 in 2020 to 25.3 DDD/100 pers. in 2022) and carbapenems (from 2.0 to 2.8 DDD/100 pers.) increased during this period (Table 5).

4. Discussion

Bacteria classified as alarm pathogens include P. aeruginosa bacilli and Acinetobacter spp. resistant to carbapenems, two other drug groups or polymyxins [22]. Unfortunately, the ability of these bacilli to produce carbapenemases is being observed at an increasing rate. In the case of P. aeruginosa, the first enzymes capable of inactivating carbapenems were IMP-1 and VIM-1. Nowadays, there are many more, and metal-β-lactamases are considered the most common [23,24]. According to EARS-Net data, the percentage of P. aeruginosa strains resistant to carbapenems after 2009 was relatively constant both in Poland and worldwide, ranging from 25 to 23%, respectively [25,26,27,28,29]. Of particular note, however, was 2018, where the percentage of resistant strains in the country was 33% [27]. This coincides with the data of the studied hospital, where the highest percentage of carbapenem-insensitive strains over the past 6 years was recorded in 2018 (30%). In contrast, the rate did not increase from 2019, and even a gradual decrease in the percentage of strains resistant to this group of drugs was noticeable. What is worrisome, however, is that the proportion of non-fermenting A. baumannii, which exhibit a wider range of resistance than Pseudomonas, is gradually increasing in hospital infections. The number of carbapenemase producers in Pseudomonas (4%) in 2021 was, in turn, lower than in Klebsiella (11% in 2021) [30]. The situation changed in 2022 the percentage of Pseudomonas MBL+ increased to 9%, while the percentage of Klebsiella pneumoniae carbapenemase-positive strains increased significantly, up to 40% (unpublished data). The remaining P. aeruginosa strains resistant to carbapenems (10% in 2021 and 12% in 2022) are less epidemic strains which do not produce carbapenemases, with a transport type of resistance. These data show that the buildup of carbapenem resistance in P. aeruginosa after the pandemic shows a lower rate than that of CPE (carbapenem-resistant Enterobacterales). In addition to resistance to β-lactam antibiotics, P. aeruginosa have also developed resistance to aminoglycosides [31,32]. In many countries in Europe, as well as worldwide, there has been a decline in the percentage of Pseudomonas strains resistant to aminoglycosides after 2009. In China, it decreased to 6.1% in 2017, while in Poland it fluctuated between 20% and 26% in 2017–2019 [26,27,28,33,34]. In the analyzed hospital, the highest number of resistant strains was isolated from infections in 2018, which accounted for about 30%, a result that exceeded the national average. In recent years, the susceptibility of Pseudomonas strains to aminoglycosides has definitely improved, and the percentage of resistance has fluctuated in the borders of 7–9%, despite the lack of restrictions on the use of these drugs in therapy. A comparison of data on the susceptibility of P. aeruginosa to piperacillin with tazobactam, has revealed that the highest percentage of resistant strains occurred in the analyzed hospital in 2018 (39%), followed by a significant increase in the proportion of susceptible strains. This situation coincided with the national trend, as there was an increase in the percentage of resistant strains in Poland after 2012, which finally reached about 37% in 2018 [27,33]. As of 2019, on the other hand, a decrease in the resistance of these bacteria to piperacillin with tazobactam was observed, shaping up at 20%, both in the hospital studied and nationally, thus approaching the global average of about 13% [26,32]. In the studied hospital, the use of antibiotics with inhibitors has increased significantly in recent years, but this mainly involves amoxicillin with clavulanate (which is inactive against Pseudomonas) and results in a decrease in its activity against many hospital pathogens. Piperacillin with tazobactam therefore still remains an active drug combination against Pseudomonas.
In Poland, the evolution of P. aeruginosa resistance to ceftazidime seems to follow a very similar pattern as resistance to piperacillin with tazobactam. In this case, too, there was a decline in the susceptibility of these bacilli observed already since 2009, reaching in 2018 the highest value in recent years (26.9% of resistant strains) [27,33]. Since 2019, in turn, an increase in the percentage of susceptible strains has been observed [28,29,35,36]. The situation was similar at the analyzed hospital, where the percentage of resistant strains fluctuated between 11% and 27% in 2017–2022, with the highest value recorded in 2018, followed by a twofold decrease in the value of this indicator. In 2019, the national and European averages were 20.1% and 14.1%, respectively, while the percentage of resistant strains in the hospital was only 12%, which was significantly lower, both compared to the national average and the average of EU/EEA countries [28]. This visibly correlates with the tendency in the hospital’s antibiotic policy not to overuse third-generation cephalosporins in therapy. Despite a temporary increase in their use at the start of the pandemic in 2020 to 15.7 DDD/100 patients days (which occurred in many countries), there was a marked decrease in the following years (to 4.7 DDD/100 patient days in 2022). The fact that the rate of resistance to this cephalosporin was low in the described hospital and still does not show an upward trend confirms the usefulness of ceftazidime as a first-line drug in the treatment of infections caused by non-fermenting P. aeruginosa.
In turn, resistance to fluoroquinolones, conditioned by mutation in chromosomal genes, leads to inactivation of DNA gyrase. It is very common for this mechanism to coexist with overactive efflux systems, resulting in an almost complete lack of sensitivity of bacterial strains. It is estimated that the most common reason for the increase in resistance to fluoroquinolones is the overuse of these antibiotics in outpatient treatment [37]. The susceptibility of P. aeruginosa to quinolones in Asian countries is quite high (86%), while in Poland the percentage of resistant strains over the past 10 years has been relatively constant at around 40% [25,26,27,28,29,33,34,35]. The situation was similar at the analyzed hospital in 2017, while in 2018 there was already a significant increase in the resistance of these bacilli, reaching 61% for levofloxacin. The year also saw record consumption for this group of antibiotics, which may have had an impact on the spread of resistant clones. On the other hand, starting in 2019, as the hospital’s antibiotic policy was programmatically geared toward reducing the use of quinolones, an increase in the susceptibility of Pseudomonas to this group of antibiotics was observed. Despite an increase in the use of antibiotics from this group during the COVID-19 pandemic in 2020 (consumption of 12.7 DDD/100 patient-days), as in the case of third-generation cephalosporins, this consumption declined sharply between 2021 and 2022 (to 7.3 DDD/100 patient-days), without generating an increase in resistance.
Data on the contribution of A. baumannii strains to infections indicate that there was a significant increase in the number of A. baumannii strains in Asian and European countries during 2020 [29]. This trend was also noticeable in the analyzed hospital, when in 2021 the number of A. baumannii strains reached the highest level in the last 6 years, also surpassing the number of resistant P. aeruginosa strains. It can be assumed that the increased number of infections caused by these bacilli was due to the higher number of hospitalized patients in severe condition, especially those hospitalized in the ICU, who developed VAP [38,39].
Strains of A. baumannii produce carbapenemases belonging to four classes: A, B, C and D according to Ambler [40]. The serine β-lactamases of the B class found in A. baumannii are most commonly KPC enzymes and GES family enzymes [41]. According to a CDC report on infections and therapeutics in the United States, A. baumannii species exhibiting resistance to carbapenems currently pose the greatest threat to public health [11,42,43]. In 2012 in Poland, the proportion of A. baumannii strains resistant to carbapenems was 38%, while in 2017–2019 the proportion has already exceeded 70% and remains at a relatively constant, high level [26,27,28,33]. The CARSS system, on the other hand, reports that in China, about 60% of Acinetobacter no longer show sensitivity to this group of antibiotics [34]. At the studied Lower Silesian Specialized Hospital, in 2017–2020, the percentage of carbapenem-resistant strains was below the national average. However, in 2021, there was a sharp increase to almost 80%, most likely due to an increase in the use of this group of antibiotics in therapy. Importantly, during this period of the pandemic there was also a significant increase in the number of Acinetobacter strains isolated in infections.
The situation of the analyzed hospital also coincides with the global situation in terms of the significant increase in resistance to carbapenems for A. baumannii strains, compared to K. pneumoniae [44,45]. Resistance of A. baumannii to aminoglycosides in recent years has remained relatively constant at a high level of 73% [28]. In the analyzed hospital in 2021, the percentage of resistant strains also exceeded 70%, while in 2017–2020 it was far below the national average. However, an upward trend for this resistance rate has been observed in recent years.
Fluoroquinolones are a group of antibiotics to which Acinetobacter bacilli show the lowest sensitivity among the antimicrobial drugs described above [11,46]. In addition, these bacteria can develop resistance to colistin, which is an antibiotic of last resort. There are two theories about the underlying processes. The first is that there is a mutation causing a complete absence of LPS and, consequently, of lipid A, which is the target site for colistin. The second, on the other hand, suggests that lipid A is present, but in a form altered by mutation of the pmrA and/or pmrB gene, which affects the lowering of colistin’s affinity for LPS [47]. Increasingly, clinicians are also encountering multidrug-resistant strains, which is probably due to prior antibiotic therapy, very often inappropriately administered [48]. It is believed that for infections caused by A. baumannii, monotherapy should not be used, but rather a combination of compounds that would condition protection against the development of resistance. For the time being, polymyxins in combination with carbapenems or tigecycline prevail in the treatment of MDR infections [49]. In Poland, the percentage of resistant strains has reached up to 87% in recent years and remains high [26,27,28,29,35]. In the case of the studied hospital, a similar situation occurred in 2017, 2018 and 2021, while in the 2019–2020 period there was a decrease in the percentage of resistant strains to about 50%, probably due to a reduction in the use of quinolones in 2019. Unfortunately, during the pandemic period there was a renewed increase in the use of antibiotics, including quinolones, in empirical therapy, including in patients with COVID-19, resulting in a huge increase in quinoline resistance for A. baumannii strains, of the order of 87%. Again, unfortunately, the programmatically applied reduction in the use of quinolones in the hospital (reduction in consumption in 2021–2022), did not result in an evident reduction in resistance, as in the case of Pseudomonas strains. It is true that the resistance of Acinetobacter strains to levofloxacin in 2022 fell to 63%, but in the case of ciprofloxacin there was an increase in resistance of up to 100%.
In conclusion, the analyses carried out at the specialized hospital allowed tracing drug resistance among the bacteria most commonly isolated from hospital-acquired infections. Knowledge of pathogen resistance and observations of emerging trends provide the opportunity to correctly apply empirical therapy with much higher effectiveness. In addition, the results made it possible to compare these data with reports of antibiotic consumption in the hospital during the period analyzed. A correlation was observed between the increase in resistance among A. baumannii strains and the increase in antibiotic consumption. Undoubtedly, these analyses need to be continued in order to track the development of resistance over a longer period of time. This is important especially after the COVID-19 pandemic, during which an uncontrolled increase in the consumption of broad-spectrum antibiotics undoubtedly contributed to a decline in the susceptibility of the hospital-acquired pathogens studied.

5. Conclusions

  • Between 2020 and 2022, the highest consumption of antibiotics in the hospital was observed, most likely due to the COVID-19 pandemic and a greater number of patients in severe condition requiring hospitalization.
  • Unfortunately, during the period under review, the number of multi-resistant strains of A. baumanii was increasing successively, which seems to be related to the increased use, especially during the pandemic, of broad-spectrum antibiotics, mainly penicillins with inhibitors, third-generation cephalosporins and carbapenems.
  • The simultaneous programmatic reduction in the use of some antibiotics, such as quinolones and third-generation cephalosporins in the post-pandemic period, seems to have had an impact on the renewed increase in strain susceptibility, especially for P. aeruginosa.

Author Contributions

Conceptualization B.M., A.J.-K., M.F.-M. and J.S.; formal analysis M.F.-M., A.J.-K., J.S., B.M., D.P. and K.W.; writing—original draft preparation, B.M., J.S., A.J.-K. and M.F.-M.; writing review and editing, J.S., A.J.-K., M.F.-M., I.C.-K. and B.M. and supervision A.J.-K. and M.F.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Medical University statutory funding SUBZ.E090.23.015.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors wish to thank the SYNEVO Medical Laboratory in Wroclaw for providing the materials.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. de Kraker, M.E.; Stewardson, A.J.; Harbarth, S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med. 2016, 13, e1002184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Basak, S.; Singh, P.; Rajurkar, M. Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J. Pathog. 2016, 2016, 4065603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 2021, 10, 1310. [Google Scholar] [CrossRef] [PubMed]
  4. Rocha, A.J.; de Oliveira Barsottini, M.R.; Rocha, R.R.; Laurindo, M.V.; de Moraes, F.L.L.; da Rocha, S.L. Pseudomonas Aeruginosa: Virulence Factors and Antibiotic Resistance Genes. Rev. Hum. Anim. Health 2019, 62, e19180503. [Google Scholar] [CrossRef]
  5. Morita, Y.; Tomida, J.; Kawamura, Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front. Microbiol. 2014, 8, 422. [Google Scholar] [CrossRef] [Green Version]
  6. Glen, K.A.; Lamont, I.L. β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens 2021, 10, 1638. [Google Scholar] [CrossRef]
  7. Howard, A.; O’Donoghue, M.; Feeney, A.; Sleator, R.D. Acinetobacter baumannii: An emerging opportunistic pathogen. Virulence 2012, 3, 243–250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Bagińska, N.; Pichlak, A.; Górski, A.; Jończyk-Matysiak, E. Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii. Virol. Sin. 2019, 34, 347–357. [Google Scholar] [CrossRef] [PubMed]
  9. Dijkshoorn, L.; Nemec, A.; Seifert, H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 2007, 5, 939–951. [Google Scholar] [CrossRef] [PubMed]
  10. Penwell, W.F.; Shapiro, A.B.; Giacobbe, R.A.; Gu, R.F.; Gao, N.; Thresher, J.; McLaughlin, R.E.; Huband, M.D.; DeJonge, B.L.; Ehmann, D.E.; et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2015, 59, 1680–1689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Kyriakidis, I.; Vasileiou, E.; Pana, Z.D.; Tragiannidis, A. Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens 2021, 10, 373. [Google Scholar] [CrossRef]
  12. Martínez-Trejo, A.; Ruiz-Ruiz, J.M.; Gonzalez-Avila, L.U.; Saldaña-Padilla, A.; Hernández-Cortez, C.; Loyola-Cruz, M.A.; Bello-López, J.M.; Castro-Escarpulli, G. Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism. Int. J. Mol. Sci. 2022, 23, 6582. [Google Scholar] [CrossRef] [PubMed]
  13. Tamma, P.D.; Avdic, E.; Li, D.X.; Dzintars, K.; Cosgrove, S.E. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern. Med. 2017, 177, 1308–1315. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Friedrich, A.W. Control of hospital acquired infections and antimicrobial resistance in Europe: The way to go. main topic. Wien. Med. Wochenschr. 2019, 169 (Suppl. S1), S25–S30. [Google Scholar] [CrossRef] [Green Version]
  15. Criteria for Diagnosis of an Outbreak in a Hospital/Health Care Facility Caused by Carbapenamase-Producing Strains of Enterobacteriaceae (CPE). Guidelines of the National Antibiotic Protection Program. Available online: http://antybiotyki.edu.pl/wpcontent/uploads/dokumenty/CPE_NDM-Ognisko-epidemiczne.pdf (accessed on 31 May 2021).
  16. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters; Version 10.0; The European Committee on Antimicrobial Susceptibility Testing: Basel, Switzerland, 2020. [Google Scholar]
  17. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Routine and Extended Internal Quality Control for MIC Determination and Disk Diffusion as Recommended by EUCAST; Version 10.0; The European Committee on Antimicrobial Susceptibility Testing: Basel, Switzerland, 2020. [Google Scholar]
  18. Skov, R.; Skov, G. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. 2017, 6, 1–47. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf (accessed on 1 June 2022).
  19. Van Dijk, K.; Voets, G.M.; Scharringa, J.; Voskuil, S.; Fluit, A.C.; Rottier, W.C.; Leverstein-Van Hall, M.A.; Cohen Stuart, J.W. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl bo ronic acid, dipicolinic acid and temocillin. Clin. Microbiol. Infect. 2014, 20, 345–349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Baraniak, A.; Grabowska, A.; Izdebski, R.; Fiett, J.; Herda, M.; Bojarska, K.; Zabicka, D.; Kania-Pudło, M.; Młynarczyk, G.; Zak-Puławska, Z.; et al. KPC-PL Study Group. Molecular characteristics of KPC-producing Enterobacteriaceae at the early stage of their dissemination in Poland, 2008–2009. Antimicrob. Agents Chemother. 2011, 55, 5493–5499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Dortet, L.; Poirel, L.; Errera, C.; Nordmann, P. CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J. Clin. Microbiol. 2014, 52, 2359–2364. [Google Scholar] [CrossRef] [Green Version]
  22. De Oliveira, D.M.P.; Forde, B.M.; Kidd, T.J.; Harris, P.N.A.; Schembri, M.A.; Beatson, S.A.; Paterson, D.L.; Walker, M.J. Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev. 2020, 33, e00181-19. [Google Scholar] [CrossRef]
  23. Liang, C.; Zhang, X.; Zhou, L.; Meng, G.; Zhong, L.; Peng, P. Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019. BMC Infect. Dis. 2021, 21, 444. [Google Scholar] [CrossRef]
  24. Ayobami, O.; Brinkwirth, S.; Eckmanns, T.; Markwart, R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: A systematic review and meta-analysis. Emerg. Microbes Infect. 2022, 11, 443–451. [Google Scholar] [CrossRef]
  25. Hu, F.; Zhu, D.; Wang, F.; Wang, M. Current Status and Trends of Antibacterial Resistance in China. Clin. Infect. Dis. 2018, 67, 128–134. [Google Scholar] [CrossRef] [PubMed]
  26. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2017; ECDC: Stockholm, Sweden, 2018. [Google Scholar]
  27. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2018; ECDC: Stockholm, Sweden, 2019. [Google Scholar]
  28. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2019; ECDC: Stockholm, Sweden, 2020. [Google Scholar]
  29. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2020; ECDC: Stockholm, Sweden, 2021. [Google Scholar]
  30. Mączyńska, B.; Frej-Mądrzak, M.; Sarowska, J.; Woronowicz, K.; Choroszy-Król, I.; Jama-Kmiecik, A. Evolution of Antibiotic Resistance in Escherichia coli and Klebsiella pneumoniae Clinical Isolates in a Multi-Profile Hospital over 5 Years (2017–2021). J. Clin. Med. 2023, 12, 2414. [Google Scholar] [CrossRef] [PubMed]
  31. Thacharodi, A.; Lamont, I.L. Aminoglycoside resistance in Pseudomonas aeruginosa: The contribution of the MexXY-OprM efflux pump varies between isolates. J. Med. Microbiol. 2022, 71. [Google Scholar] [CrossRef]
  32. Dou, Q.; Zhu, Y.; Li, C.; Bian, Z.; Song, H.; Zhang, R.; Wang, Y.; Zhang, X.; Wang, Y. 4F-Indole Enhances the Susceptibility of Pseudomonas aeruginosa to Aminoglycoside Antibiotics. Microbiol. Spectr. 2023, 11, e0451922. [Google Scholar] [CrossRef]
  33. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2012. In Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); ECDC: Stockholm, Sweden, 2013. [Google Scholar]
  34. Yang, P.; Chen, Y.; Jiang, S.; Shen, P.; Lu, X.; Xiao, Y. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014. BMC Infect. Dis. 2020, 20, 269. [Google Scholar] [CrossRef] [Green Version]
  35. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2021; ECDC: Stockholm, Sweden, 2022. [Google Scholar]
  36. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net): Annual Epidemiological Report for 2022; ECDC: Stockholm, Sweden, 2023. [Google Scholar]
  37. Hooper, D.C. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 2001, 7, 337–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Izdebski, R.; Fiett, J.; Hryniewicz, W.; Gniadkowski, M. Molecular analysis of Acinetobacter baumannii isolates from invasive infections in 2009 in Poland. J. Clin. Med. 2012, 50, 3813–3815. [Google Scholar] [CrossRef] [Green Version]
  39. Hou, J.; Long, X.; Wang, X.; Li, L.; Mao, D.; Luo, Y.; Ren, H. Global trend of antimicrobial resistance in common bacterial pathogens in response to antibiotic consumption. J. Hazard. Mater. 2023, 442, 130042. [Google Scholar] [CrossRef]
  40. Zhao, W.H.; Hu, Z.Q. Acinetobacter: A potential reservoir and dispenser for β-lactamases. Crit. Rev. Microbiol. 2012, 38, 30–51. [Google Scholar] [CrossRef]
  41. Hammoudi Halat, D.; Ayoub Moubareck, C. The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria. Antibiotics 2020, 9, 186. [Google Scholar] [CrossRef] [Green Version]
  42. Camargo, C.H.; Cunha, M.P.V.; de Barcellos, T.A.F.; Bueno, M.S.; Bertani, A.M.J.; Dos Santos, C.A.; Nagamori, F.O.; Takagi, E.H.; Chimara, E.; de Carvalho, E.; et al. Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC25. Int. J. Antimicrob. Agents 2020, 56, 106195. [Google Scholar] [CrossRef] [PubMed]
  43. Bush, K.; Bradford, P.A. Epidemiology of β-Lactamase-Producing Pathogens. Clin. Microbiol. Rev. 2020, 33, e00047-19. [Google Scholar] [CrossRef] [PubMed]
  44. Vázquez-López, R.; Solano-Gálvez, S.G.; Juárez Vignon-Whaley, J.J.; Abello Vaamonde, J.A.; Padró Alonzo, L.A.; Rivera Reséndiz, A.; Muleiro Álvarez, M.; Vega López, E.N.; Franyuti-Kelly, G.; Álvarez-Hernández, D.A.; et al. Acinetobacter baumannii Resistance: A Real Challenge for Clinicians. Antibiotics 2020, 9, 205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Serio, A.W.; Keepers, T.; Andrews, L.; Krause, K.M. Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. EcoSal Plus 2018, 8. [Google Scholar] [CrossRef] [Green Version]
  46. Fàbrega, A.; Madurga, S.; Giralt, E.; Vila, J. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2009, 2, 40–61. [Google Scholar] [CrossRef] [Green Version]
  47. Novović, K.; Jovčić, B. Colistin Resistance in Acinetobacter baumannii: Molecular Mechanisms and Epidemiology. Antibiotics 2023, 12, 516. [Google Scholar] [CrossRef]
  48. Pustijanac, E.; Hrenović, J.; Vranić-Ladavac, M.; Močenić, M.; Karčić, N.; Lazarić Stefanović, L.; Hrstić, I.; Lončarić, J.; Šeruga Musić, M.; Drčelić, M.; et al. Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic. Pathogens 2023, 12, 410. [Google Scholar] [CrossRef]
  49. Mantzana, P.; Protonotariou, E.; Kassomenaki, A.; Meletis, G.; Tychala, A.; Keskilidou, E.; Arhonti, M.; Katsanou, C.; Daviti, A.; Vasilaki, O.; et al. In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae. Antibiotics 2023, 12, 93. [Google Scholar] [CrossRef]
Jcm 12 05020 g001 550
Figure 1. Comparison of the number of P. aeruginosa and A. baumannii strains isolated from infections between 2017 and 2022.
Figure 1. Comparison of the number of P. aeruginosa and A. baumannii strains isolated from infections between 2017 and 2022.
Jcm 12 05020 g001
Jcm 12 05020 g002 550
Figure 2. Percentage of P. aeruginosa strains resistant to cephalosporins and piperacillin with tazobactam.
Figure 2. Percentage of P. aeruginosa strains resistant to cephalosporins and piperacillin with tazobactam.
Jcm 12 05020 g002
Jcm 12 05020 g003 550
Figure 3. Percentage of P. aeruginosa strains resistant to carbapenems.
Figure 3. Percentage of P. aeruginosa strains resistant to carbapenems.
Jcm 12 05020 g003
Jcm 12 05020 g004 550
Figure 4. Comparison of the percentage of P. aeruginosa strains sensitive and resistant to carbapenems and strains producing MBL (+) carbapenemases in 2021 and 2022.
Figure 4. Comparison of the percentage of P. aeruginosa strains sensitive and resistant to carbapenems and strains producing MBL (+) carbapenemases in 2021 and 2022.
Jcm 12 05020 g004
Jcm 12 05020 g005 550
Figure 5. Percentage of P. aeruginosa strains resistant to aminoglycosides.
Figure 5. Percentage of P. aeruginosa strains resistant to aminoglycosides.
Jcm 12 05020 g005
Jcm 12 05020 g006 550
Figure 6. Percentage of P. aeruginosa strains resistant to quinolones.
Figure 6. Percentage of P. aeruginosa strains resistant to quinolones.
Jcm 12 05020 g006
Jcm 12 05020 g007 550
Figure 7. Percentage of A. baumannii strains resistant to carbapenems between 2017 and 2022.
Figure 7. Percentage of A. baumannii strains resistant to carbapenems between 2017 and 2022.
Jcm 12 05020 g007
Jcm 12 05020 g008 550
Figure 8. Percentage of A. baumannii strains resistant to aminoglycosides in 2017–2022.
Figure 8. Percentage of A. baumannii strains resistant to aminoglycosides in 2017–2022.
Jcm 12 05020 g008
Jcm 12 05020 g009 550
Figure 9. Percentage of A. baumannii strains resistant to quinolones in 2017–2022.
Figure 9. Percentage of A. baumannii strains resistant to quinolones in 2017–2022.
Jcm 12 05020 g009
Table
Table 1. Number of tested strains of particular microorganisms isolated from infections in 2017–2022.
Table 1. Number of tested strains of particular microorganisms isolated from infections in 2017–2022.
Year/Strains201720182019202020212022
Pseudomonas
aeruginosa		173202158147146149
Acinetobacter
baumannii		123104476616098
Total296306205213306247
Table
Table 2. Antibiotics to which the sensitivity of the tested strains was determined.
Table 2. Antibiotics to which the sensitivity of the tested strains was determined.
StrainSelected Antibiotics
Pseudomonas aeruginosaGentamicin, amikacin, ciprofloxacin, levofloxacin, meropenem, imipenem, ceftazidime, cefepime, piperacillin/tazobactam
Acinetobacter baumaniiGentamicin, amikacin, ciprofloxacin, levofloxacin, meropenem, imipenem
Table
Table 3. Number of all strains isolated from infections in 2017–2022 (1 strain = 1 patient).
Table 3. Number of all strains isolated from infections in 2017–2022 (1 strain = 1 patient).
Year/Strain201720182019202020212022
Escherichia coli791917851742770822
Klebsiella pneumoniae320404303270338473
Pseudomonas aeruginosa173202158147146149
Acinetobacter baumannii123104476616098
Staphylococcus aureus532627445365348324
Enterococcus faecalis318284243249350295
Enterococcus faecium4997687387105
Streptococcus pneumoniae386145373032
Other microorganisms234139478934
Total236727372199199623182332
Table
Table 4. Percentage (%) of isolated Pseudomonas aeruginosa and Acinetobacter baumanii strains in relation to all strains isolated from infections in 2017–2022.
Table 4. Percentage (%) of isolated Pseudomonas aeruginosa and Acinetobacter baumanii strains in relation to all strains isolated from infections in 2017–2022.
Year/Strain201720182019202020212022
Pseudomonas aeruginosa7.37.47.27.46.26.4
Acinetobacter baumannii5.23.82.13.36.94.2
Table
Table 5. Antibiotic consumption in the hospital during the studied 6-year period: 2017–2022 (in DDD/100 Patient Days).
Table 5. Antibiotic consumption in the hospital during the studied 6-year period: 2017–2022 (in DDD/100 Patient Days).
Antibiotic Consumption in the Hospital (in DDD/100 Patient Days)
YearTETPESPES+in.C IIC IIIC IVKARBMAKLINKAMCHGPPOLTotal
20171.00.87.39.32.60.10.93.40.20.85,70.60.342.4
20180.60.77.211.03.10.21.20.60.60.69,30.90.444.0
20192.41.38.41.42.70.22.42.40.80.72,51.30.234.7
20200.81.48.32.615.70.32.00.61.11.012.71.10.458.3
20210.73.922.31.87.40.22.10.81.01.08.31.41.860.5
20220.73.325.31.84.70.22.80.81.21.57.31.41.662.9
TET—tetracyclines, PES—penicillins, PES+in.—penicillins with inhibitors, C II—second-generation cephalosporins, C III—third-generation cephalosporins, C IV—fourth-generation cephalosporins, KARB—carbapenems, MAK—macrolides, AM—aminoglycosides, CH—quinolones, GP—glycopeptides, POL—polymyxins.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mączyńska, B.; Jama-Kmiecik, A.; Sarowska, J.; Woronowicz, K.; Choroszy-Król, I.; Piątek, D.; Frej-Mądrzak, M. Changes in Antibiotic Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Clinical Isolates in a Multi-Profile Hospital in Years 2017–2022 in Wroclaw, Poland. J. Clin. Med. 2023, 12, 5020. https://doi.org/10.3390/jcm12155020

AMA Style

Mączyńska B, Jama-Kmiecik A, Sarowska J, Woronowicz K, Choroszy-Król I, Piątek D, Frej-Mądrzak M. Changes in Antibiotic Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Clinical Isolates in a Multi-Profile Hospital in Years 2017–2022 in Wroclaw, Poland. Journal of Clinical Medicine. 2023; 12(15):5020. https://doi.org/10.3390/jcm12155020

Chicago/Turabian Style

Mączyńska, Beata, Agnieszka Jama-Kmiecik, Jolanta Sarowska, Krystyna Woronowicz, Irena Choroszy-Król, Daniel Piątek, and Magdalena Frej-Mądrzak. 2023. "Changes in Antibiotic Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Clinical Isolates in a Multi-Profile Hospital in Years 2017–2022 in Wroclaw, Poland" Journal of Clinical Medicine 12, no. 15: 5020. https://doi.org/10.3390/jcm12155020

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop